AI Article Synopsis
Article Abstract
Saquinavir boosted with low-dose ritonavir given with zidovudine and lamivudine was well tolerated by pregnant women and their infants. All mothers had <400 human immunodeficiency virus type 1 RNA copies/ml at delivery. Two had elevated liver transaminases and amylase. Seven infant adverse events were possibly treatment related (anemia, neutropenia, and hyperbilirubinemia).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1891372 | PMC |
| http://dx.doi.org/10.1128/AAC.00871-06 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of corticosteroids on initiation and half-year durability of humoral response in COVID-19 survivors.
Chin Med J Pulm Crit Care Med
March 2024
National Health Commission Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 102629, China.
Background: The impact of corticosteroids on humoral responses in coronavirus disease 2019 (COVID-19) survivors during the acute phase and subsequent 6-month period remains unknown. This study aimed to determine how the use of corticosteroids influences the initiation and duration of humoral responses in COVID-19 survivors 6 months after infection onset.
Methods: We used kinetic antibody data from the lopinavir-ritonavir trial conducted at Jin Yin-Tan Hospital in January 2020, which involved adults hospitalized with severe COVID-19 (LOTUS, ChiCTR2000029308).
Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers.
Clin Pharmacokinet
April 2024
Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Medical Faculty of Heidelberg, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Article Synopsis
- The study aimed to understand how a 5-day low-dose ritonavir treatment impacts the pharmacokinetics of three factor Xa inhibitors (FXaI) used in COVID-19 therapy, alongside monitoring the activities of specific cytochrome P450 enzymes.
- Results indicated ritonavir significantly increased the exposure of apixaban, edoxaban, and rivaroxaban, with a strong inhibition of CYP3A4 and moderate induction of CYP2C19, while CYP2D6 remained unchanged.
- The findings suggest a need to potentially reduce rivaroxaban doses during short-term ritonavir treatment, especially for patients on high maintenance doses, due to the varying effects on drug metabolism over time.
Influence of a Short Course of Ritonavir Used as Booster in Antiviral Therapies Against SARS-CoV-2 on the Exposure of Atorvastatin and Rosuvastatin.
Cardiovasc Drugs Ther
December 2023
Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Medical Faculty of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Purpose: Early antiviral treatment with nirmatrelvir/ritonavir is recommended for SARS-CoV-2-infected patients at high risk for severe courses. Such patients are usually chronically ill and susceptible to adverse drug interactions caused by ritonavir. We investigated the interactions of short-term low-dose ritonavir therapy with atorvastatin and rosuvastatin, two statins commonly used in this population.
View Article and Find Full Text PDFEfficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial.
Lancet Reg Health West Pac
September 2023
Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Third People's Hospital of Shenzhen, China.
Background: SIM0417 (SSD8432) is an orally administered coronavirus main proteinase (3CL) inhibitor with potential anti-SARS-CoV-2 activity. This study aimed to evaluate the efficacy and safety of SIM0417 plus ritonavir (a pharmacokinetic enhancer) in adults with COVID-19.
Methods: This was a randomised, double-blind, placebo-controlled, phase 1b study in China.
Celecoxib Oral Solution and the Benefits of Self-Microemulsifying Drug Delivery Systems (SMEDDS) Technology: A Narrative Review.
Pain Ther
October 2023
Collegium Pharmaceutical, Inc., 100 Technology Center Drive, Suite 300, Stoughton, MA, 02072, USA.
Introduction: The oral route of drug delivery is the most widespread and preferred route of administration, but it has several limitations, including variable pharmacokinetics (PK), reduced dissolution and absorption, and gastrointestinal irritation. Further, many compounds have low aqueous solubility, which also limits intestinal absorption.
Methods: For this narrative review, we conducted a literature search of PubMed until August 2022, focusing on emulsions, microemulsions, nanoemulsions, and self-emulsifying drug delivery systems.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!